Late Clinical Events After Drug-Eluting Stents

This publication has 43 references indexed in Scilit:

• Impact of Target Lesion and Nontarget Lesion Cardiac Events on 5-Year Clinical Outcomes After Sirolimus-Eluting or Bare-Metal Stenting
  JACC: Cardiovascular Interventions, 2009
• Greater Clinical Benefit of More Intensive Oral Antiplatelet Therapy With Prasugrel in Patients With Diabetes Mellitus in the Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition With Prasugrel–Thrombolysis in Myocardial Infarction 38
  Circulation, 2008
• Long-Term Outcomes by Clopidogrel Duration and Stent Type in a Diabetic Population With De Novo Coronary Artery Lesions
  JACC, 2008
• The Relation Between Clinical Features, Angiographic Findings, and the Target Lesion Revascularization Rate in Patients Receiving the Endeavor Zotarolimus-Eluting Stent for Treatment of Native Coronary Artery Disease: An Analysis of ENDEAVOR I, ENDEAVOR II, ENDEAVOR II Continued Access Registry, and ENDEAVOR III
  The American Journal of Cardiology, 2007
• Optimal Medical Therapy with or without PCI for Stable Coronary Disease
  New England Journal of Medicine, 2007
• Sirolimus-Eluting Stents at Two Years: A Pooled Analysis of SIRIUS, E-SIRIUS, and C-SIRIUS With Emphasis on Late Revascularizations and Stent Thromboses
  The American Journal of Cardiology, 2006
• Two-Year Outcomes After Sirolimus-Eluting Stent Implantation
  JACC, 2006
• Clinical Efficacy of Polymer-Based Paclitaxel-Eluting Stents in the Treatment of Complex, Long Coronary Artery Lesions From a Multicenter, Randomized Trial
  Circulation, 2005
• MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20 536 high-risk individuals: a randomised placebocontrolled trial
  The Lancet, 2002
• Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels
  New England Journal of Medicine, 1998